Lv6
2810 积分 2023-05-22 加入
GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
17小时前
已完结
Noninvasive Assessment of Liver Fibrosis
2天前
已完结
Personalized Prediction of the Individual Risk of Liver-Related Events in Metabolic Dysfunction–Associated Steatotic Liver Disease Using the Dynamics of Noninvasive Tests
3天前
待确认
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
3天前
已完结
Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease
4天前
已完结
Comparative efficacy of phase 2–3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis
20天前
已完结
Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis
21天前
已完结
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
26天前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study
26天前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
27天前
已完结
皖公网安备34019202002308
